Allisartan Isoproxil

TargetMol
Product Code: TAR-T26594
Supplier: TargetMol
CodeSizePrice
TAR-T26594-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-2mg2mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-5mg5mg£430.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-1mL1 mL * 10 mM (in DMSO)£533.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-10mg10mg£599.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-100mg100mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26594-500mg500mg£3,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Allisartan Isoproxil is a nonpeptide antagonist of angiotensin II receptor and can be used in studies about hypertension and heart diseases.
CAS:
947331-05-7
Formula:
C27H29ClN6O5
Molecular Weight:
553.01
Pathway:
Endocrinology/Hormones
Purity:
0.9978
SMILES:
O=C(OCOC(=O)C1=C(Cl)N=C(N1CC=2C=CC(=CC2)C=3C=CC=CC3C4=NN=NN4)CCCC)OC(C)C
Target:
RAAS

References

1. Jin Q, et al. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF??B signalling pathway in diabetic cardiomyopathy rats. Mol Med Rep. 2021 Mar;23(3):215. 2. Zhang G, et al. Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial. Adv Ther. 2020 Aug;37(8):3551-3561.